Table 1 Open in new tab Clinical...

	Number of patients	Number of serum samples (first available sample median days from episode onset, range)	Number of CSF samples (first available sample median days from episode onset, range)	Median age (range), years, at disease onset (or time of sampling, for controls)	Female (%)	OT detected (%)
Cases
Definite NMDAR-antibody encephalitis^a	108	285 (26, 0–3029)	60 (27, 0–579)	20.5 (1–74)	78 (72%)	29 (27%^b)
Controls
Healthy volunteers	55	55	N/A	36 (20–71)	64	N/A
Traumatic brain injury	58	58	31	39 (21–72)	23	N/A
Bipolar disorder	222	395	N/A	44 (18–62)	54	N/A
Total controls	335	508	31	43 (18–72)	50	N/A

	Number of patients	Number of serum samples (first available sample median days from episode onset, range)	Number of CSF samples (first available sample median days from episode onset, range)	Median age (range), years, at disease onset (or time of sampling, for controls)	Female (%)	OT detected (%)
Cases
Definite NMDAR-antibody encephalitis^a	108	285 (26, 0–3029)	60 (27, 0–579)	20.5 (1–74)	78 (72%)	29 (27%^b)
Controls
Healthy volunteers	55	55	N/A	36 (20–71)	64	N/A
Traumatic brain injury	58	58	31	39 (21–72)	23	N/A
Bipolar disorder	222	395	N/A	44 (18–62)	54	N/A
Total controls	335	508	31	43 (18–72)	50	N/A

Table 1

Clinical summaries and serum/CSF samples tested from patients with definite NMDAR-antibody encephalitis and disease controls

	Number of patients	Number of serum samples (first available sample median days from episode onset, range)	Number of CSF samples (first available sample median days from episode onset, range)	Median age (range), years, at disease onset (or time of sampling, for controls)	Female (%)	OT detected (%)
Cases
Definite NMDAR-antibody encephalitis^a	108	285 (26, 0–3029)	60 (27, 0–579)	20.5 (1–74)	78 (72%)	29 (27%^b)
Controls
Healthy volunteers	55	55	N/A	36 (20–71)	64	N/A
Traumatic brain injury	58	58	31	39 (21–72)	23	N/A
Bipolar disorder	222	395	N/A	44 (18–62)	54	N/A
Total controls	335	508	31	43 (18–72)	50	N/A

	Number of patients	Number of serum samples (first available sample median days from episode onset, range)	Number of CSF samples (first available sample median days from episode onset, range)	Median age (range), years, at disease onset (or time of sampling, for controls)	Female (%)	OT detected (%)
Cases
Definite NMDAR-antibody encephalitis^a	108	285 (26, 0–3029)	60 (27, 0–579)	20.5 (1–74)	78 (72%)	29 (27%^b)
Controls
Healthy volunteers	55	55	N/A	36 (20–71)	64	N/A
Traumatic brain injury	58	58	31	39 (21–72)	23	N/A
Bipolar disorder	222	395	N/A	44 (18–62)	54	N/A
Total controls	335	508	31	43 (18–72)	50	N/A

N/A = not available.

All patients had NR1-IgG autoantibodies detectable in CSF and a compatible clinical syndrome.

No tumours were documented in the male cases.